Intracranial  ||| S:0 E:13 ||| NNP
and  ||| S:13 E:17 ||| CC
cerebral  ||| S:17 E:26 ||| JJ
perfusion  ||| S:26 E:36 ||| JJ
pressure  ||| S:36 E:45 ||| NN
in  ||| S:45 E:48 ||| IN
neurosurgical  ||| S:48 E:62 ||| JJ
patients  ||| S:62 E:71 ||| NNS
during  ||| S:71 E:78 ||| IN
anaesthesia  ||| S:78 E:90 ||| NN
with  ||| S:90 E:95 ||| IN
xenon  ||| S:95 E:101 ||| NN
Despite  ||| S:101 E:109 ||| IN
difficulties  ||| S:109 E:122 ||| NNS
in  ||| S:122 E:125 ||| IN
providing  ||| S:125 E:135 ||| VBG
xenon  ||| S:135 E:141 ||| JJ
anaesthesia ||| S:141 E:152 ||| NN
,  ||| S:152 E:154 ||| ,
xenon  ||| S:154 E:160 ||| VBD
still  ||| S:160 E:166 ||| RB
seems  ||| S:166 E:172 ||| VBZ
to  ||| S:172 E:175 ||| TO
be  ||| S:175 E:178 ||| VB
attractive  ||| S:178 E:189 ||| JJ
for  ||| S:189 E:193 ||| IN
neurosurgical  ||| S:193 E:207 ||| JJ
procedures ||| S:207 E:217 ||| NNS
.  ||| S:217 E:219 ||| .
But  ||| S:219 E:223 ||| CC
data  ||| S:223 E:228 ||| NNS
upon  ||| S:228 E:233 ||| IN
its  ||| S:233 E:237 ||| PRP$
effect  ||| S:237 E:244 ||| NN
on  ||| S:244 E:247 ||| IN
intracranial  ||| S:247 E:260 ||| NNS
( ||| S:260 E:261 ||| -LRB-
ICP ||| S:261 E:264 ||| NNP
)  ||| S:264 E:266 ||| -RRB-
and  ||| S:266 E:270 ||| CC
cerebral  ||| S:270 E:279 ||| JJ
perfusion  ||| S:279 E:289 ||| JJ
pressure  ||| S:289 E:298 ||| NN
( ||| S:298 E:299 ||| -LRB-
CPP ||| S:299 E:302 ||| NNP
)  ||| S:302 E:304 ||| -RRB-
remains  ||| S:304 E:312 ||| VBZ
controversial ||| S:312 E:325 ||| JJ
.  ||| S:325 E:327 ||| .
We  ||| S:327 E:330 ||| PRP
monitored  ||| S:330 E:340 ||| VBD
ICP  ||| S:340 E:344 ||| NNP
and  ||| S:344 E:348 ||| CC
CPP  ||| S:348 E:352 ||| NNP
in  ||| S:352 E:355 ||| IN
patients  ||| S:355 E:364 ||| NNS
with  ||| S:364 E:369 ||| IN
or  ||| S:369 E:372 ||| CC
without  ||| S:372 E:380 ||| IN
intracranial  ||| S:380 E:393 ||| JJ
hypertension  ||| S:393 E:406 ||| NN
during  ||| S:406 E:413 ||| IN
xenon  ||| S:413 E:419 ||| JJ
inhalation  ||| S:419 E:430 ||| NN
in  ||| S:430 E:433 ||| IN
different  ||| S:433 E:443 ||| JJ
concentrations ||| S:443 E:457 ||| NNS
.  ||| S:457 E:459 ||| .
Our  ||| S:459 E:463 ||| PRP$
results  ||| S:463 E:471 ||| NNS
suggest  ||| S:471 E:479 ||| VBP
that  ||| S:479 E:484 ||| DT
caution  ||| S:484 E:492 ||| NN
should  ||| S:492 E:499 ||| MD
be  ||| S:499 E:502 ||| VB
used  ||| S:502 E:507 ||| VBN
while  ||| S:507 E:513 ||| IN
inhaling  ||| S:513 E:522 ||| JJ
xenon  ||| S:522 E:528 ||| NN
in  ||| S:528 E:531 ||| IN
high  ||| S:531 E:536 ||| JJ
anaesthetic  ||| S:536 E:548 ||| JJ
concentration  ||| S:548 E:562 ||| NN
in  ||| S:562 E:565 ||| IN
patients  ||| S:565 E:574 ||| NNS
wiith  ||| S:574 E:580 ||| VBP
known  ||| S:580 E:586 ||| VBN
intracranial  ||| S:586 E:599 ||| JJ
hypertension ||| S:599 E:611 ||| NN
.  ||| S:611 E:613 ||| .
We  ||| S:613 E:616 ||| PRP
also  ||| S:616 E:621 ||| RB
address  ||| S:621 E:629 ||| VB
new  ||| S:629 E:633 ||| JJ
possibilities  ||| S:633 E:647 ||| NNS
of  ||| S:647 E:650 ||| IN
xenon  ||| S:650 E:656 ||| JJ
use ||| S:656 E:659 ||| NN
,  ||| S:659 E:661 ||| ,
e.g. ||| S:661 E:665 ||| NNP
,  ||| S:665 E:667 ||| ,
for  ||| S:667 E:671 ||| IN
sedation  ||| S:671 E:680 ||| NN
in  ||| S:680 E:683 ||| IN
neurosurgery ||| S:683 E:695 ||| NN
.  ||| S:695 E:697 ||| .
The  ||| S:697 E:701 ||| DT
study  ||| S:701 E:707 ||| NN
was  ||| S:707 E:711 ||| VBD
supported  ||| S:711 E:721 ||| VBN
by  ||| S:721 E:724 ||| IN
Russian  ||| S:724 E:732 ||| NNP
Fund  ||| S:732 E:737 ||| NNP
for  ||| S:737 E:741 ||| IN
Fundamental  ||| S:741 E:753 ||| NNP
Research ||| S:753 E:761 ||| NNP
,  ||| S:761 E:763 ||| ,
grant  ||| S:763 E:769 ||| NN
number  ||| S:769 E:776 ||| NN
13-04-01640 ||| S:776 E:787 ||| NN
.  ||| S:787 E:789 ||| .
